Effect of dirithromycin on Haemophilus influenzae infection of the respiratory mucosa.
Macrolides have properties other than their antibiotic action which may benefit patients with airway infections. We have investigated the effect of dirithromycin (0.125 to 8.0 microg/ml) on the interaction of Haemophilus influenzae with respiratory mucosa in vitro using human nasal epithelium, adenoid tissue, and bovine trachea. Dirithromycin did not affect the ciliary beat frequency of the nasal epithelium or the transport of mucus on bovine trachea, but dirithromycin (1 microg/ml) did reduce the slowing of the ciliary beat frequency and the damage to the nasal epithelium caused by H. influenzae broth culture filtrate. Amoxicillin (2 microg/ml) did not reduce the effects of the H. influenzae broth culture filtrate. H. influenzae infection of the organ cultures for 24 h caused mucosal damage and the loss of ciliated cells. Bacteria adhered to damaged epithelium and to a lesser extent to mucus and unciliated cells. Incubation of H. influenzae with dirithromycin at sub-MICs (0.125 and 0.5 microg/ml) prior to infection of the organ cultures did not reduce the mucosal damage caused by bacterial infection. By contrast, incubation of adenoid tissue with dirithromycin (0.125 to 1.0 microg/ml) for 4 h prior to assembling the organ culture reduced the mucosal damage caused by subsequent H. influenzae infection by as much as 50%. The number of bacteria adherent to the mucosa was reduced, although the tissue that had been incubated with dirithromycin (0.125 and 0.5 microg/ml) did not inhibit bacterial growth. This was achieved by a reduction in the amount of damaged epithelium to which H. influenzae adhered and a reduction in the density of bacteria adhering to mucus. We conclude that dirithromycin at concentrations achievable in vivo markedly reduces the mucosal damage caused by H. influenzae infection due to a cytoprotective effect.
Rutman
A
A
Host Defence Unit, Imperial College of Science, Technology and Medicine, National Heart and Lung Institute, London, United Kingdom.
Dowling
R
R
Wills
P
P
Feldman
C
C
Cole
P J
PJ
Wilson
R
R
D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004917:Erythromycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D006192:Haemophilus Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D006193:Haemophilus influenzae; D006801:Humans; D066298:In Vitro Techniques; D018942:Macrolides; D008855:Microscopy, Electron, Scanning; D009079:Mucociliary Clearance / Q000187:drug effects; D009297:Nasal Mucosa / Q000382:microbiology* / Q000473:pathology*; D010406:Penicillins / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D018942:Macrolides; D010406:Penicillins; C053853:dirithromycin; D004917:Erythromycin; D000658:Amoxicillin